File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antithrombotic therapy and the risk of new-onset dementia in elderly patients with atrial fibrillation

TitleAntithrombotic therapy and the risk of new-onset dementia in elderly patients with atrial fibrillation
Authors
KeywordsNeurology
Cardiology
Dementia
Issue Date2020
PublisherBMJ Publishing Group. The Journal's web site is located at http://www.postgradmedj.com
Citation
Postgraduate medical journal, 2020, v. 98 n. 1156, p. 98-103 How to Cite?
AbstractBackground: Atrial fibrillation (AF) is associated with an increased risk of dementia. Little is known about the relationship of antithrombotic therapy and the risk of dementia in patients with AF without clinical stroke. Method: This was an observational study based on a hospital AF registry. Patients aged 65-85 years at the time of AF diagnosis were identified via the computerised database of the clinical management system. Patients with prior stroke or known cognitive dysfunction were excluded. The primary outcome was newly diagnosed dementia during the follow-up period. Results: 3284 patients (mean age 76.4±5.3 years, 51.6% male) were included for analysis. The mean CHA2DS2-VASc score was 3.94±1.44. 18.5% patients were prescribed warfarin, 39.8% were prescribed aspirin and 41.7% were prescribed no antithrombotic therapy. After a mean follow-up of 3.6 years, 71 patients (2.2%) developed dementia, giving rise to an incidence of 0.61%/year. The incidence of dementia were 1.04%/year, 0.69%/year and 0.14%/year for patients on no therapy, aspirin and warfarin, respectively. Both univariate and multivariate analyses showed that age ≥75 years, female gender and high CHA2DS2-VASc score were associated with significantly higher risk of dementia; warfarin use was associated with significantly lower risk of dementia (HR: 0.14%, 95% CI 0.05 to 0.36, p<0.001). Patients on warfarin with time in therapeutic range (TTR) ≥65% had a non-significant trend towards a lower risk of dementia compared with those with TTR <65%. Conclusion: In elderly AF patients, warfarin therapy was associated with a significantly lower risk of new-onset dementia compared those with no therapy or aspirin.
Persistent Identifierhttp://hdl.handle.net/10722/308302
ISSN
2021 Impact Factor: 4.973
2020 SCImago Journal Rankings: 0.568
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, CK-
dc.contributor.authorHuang, D-
dc.contributor.authorZHOU, M-
dc.contributor.authorHai, SHJJ-
dc.contributor.authorYue, WS-
dc.contributor.authorLi, WH-
dc.contributor.authorYin, LX-
dc.contributor.authorZuo, ML-
dc.contributor.authorFeng, YQ-
dc.contributor.authorTan, N-
dc.contributor.authorChen, JY-
dc.contributor.authorKwan, J-
dc.contributor.authorSiu, DCW-
dc.date.accessioned2021-11-12T13:45:21Z-
dc.date.available2021-11-12T13:45:21Z-
dc.date.issued2020-
dc.identifier.citationPostgraduate medical journal, 2020, v. 98 n. 1156, p. 98-103-
dc.identifier.issn0032-5473-
dc.identifier.urihttp://hdl.handle.net/10722/308302-
dc.description.abstractBackground: Atrial fibrillation (AF) is associated with an increased risk of dementia. Little is known about the relationship of antithrombotic therapy and the risk of dementia in patients with AF without clinical stroke. Method: This was an observational study based on a hospital AF registry. Patients aged 65-85 years at the time of AF diagnosis were identified via the computerised database of the clinical management system. Patients with prior stroke or known cognitive dysfunction were excluded. The primary outcome was newly diagnosed dementia during the follow-up period. Results: 3284 patients (mean age 76.4±5.3 years, 51.6% male) were included for analysis. The mean CHA2DS2-VASc score was 3.94±1.44. 18.5% patients were prescribed warfarin, 39.8% were prescribed aspirin and 41.7% were prescribed no antithrombotic therapy. After a mean follow-up of 3.6 years, 71 patients (2.2%) developed dementia, giving rise to an incidence of 0.61%/year. The incidence of dementia were 1.04%/year, 0.69%/year and 0.14%/year for patients on no therapy, aspirin and warfarin, respectively. Both univariate and multivariate analyses showed that age ≥75 years, female gender and high CHA2DS2-VASc score were associated with significantly higher risk of dementia; warfarin use was associated with significantly lower risk of dementia (HR: 0.14%, 95% CI 0.05 to 0.36, p<0.001). Patients on warfarin with time in therapeutic range (TTR) ≥65% had a non-significant trend towards a lower risk of dementia compared with those with TTR <65%. Conclusion: In elderly AF patients, warfarin therapy was associated with a significantly lower risk of new-onset dementia compared those with no therapy or aspirin.-
dc.languageeng-
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://www.postgradmedj.com-
dc.relation.ispartofPostgraduate medical journal-
dc.rightsPostgraduate medical journal. Copyright © BMJ Publishing Group.-
dc.rightsAuthor’s Accepted Manuscript This article has been accepted for publication in [Journal, Year] following peer review, and the Version of Record can be accessed online at [insert full DOI eg. http://dx.doi.org/10.1136/xxxxx © Authors (or their employer(s)) OR © BMJ Publishing Group Ltd ( for assignments of BMJ Case Reports) <year>-
dc.subjectNeurology-
dc.subjectCardiology-
dc.subjectDementia-
dc.titleAntithrombotic therapy and the risk of new-onset dementia in elderly patients with atrial fibrillation-
dc.typeArticle-
dc.identifier.emailHai, SHJJ: haishjj@hku.hk-
dc.identifier.emailSiu, DCW: cwdsiu@hkucc.hku.hk-
dc.identifier.authorityHai, SHJJ=rp02047-
dc.identifier.authoritySiu, DCW=rp00534-
dc.identifier.doi10.1136/postgradmedj-2020-137916-
dc.identifier.pmid33184131-
dc.identifier.scopuseid_2-s2.0-85096604581-
dc.identifier.hkuros329696-
dc.identifier.volume98-
dc.identifier.issue1156-
dc.identifier.spage98-
dc.identifier.epage103-
dc.identifier.isiWOS:000746636100006-
dc.publisher.placeGreat Britain-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats